Erin Van Winkle
YOU?
Author Swipe
View article: 54O Health state impacts of afamitresgene autoleucel (afami-cel) in advanced synovial sarcoma and myxoid/round cell liposarcoma: SPEARHEAD-1 cohort 1
54O Health state impacts of afamitresgene autoleucel (afami-cel) in advanced synovial sarcoma and myxoid/round cell liposarcoma: SPEARHEAD-1 cohort 1 Open
Afamitresgene autoleucel (afami-cel) is an autologous engineered T-cell receptor T-cell therapy targeting tumors expressing melanoma-associated antigen A4 (MAGE-A4). Cohort 1 of the phase 2 SPEARHEAD-1 trial showed a response rate of 38.6%…
View article: Data from Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 <sup>c259</sup>T Cells in Synovial Sarcoma
Data from Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 <sup>c259</sup>T Cells in Synovial Sarcoma Open
We evaluated the safety and activity of autologous T cells expressing NY-ESO-1c259, an affinity-enhanced T-cell receptor (TCR) recognizing an HLA-A2–restricted NY-ESO-1/LAGE1a–derived peptide, in patients with metastatic synovial sarcoma (…
View article: Data from Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 <sup>c259</sup>T Cells in Synovial Sarcoma
Data from Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 <sup>c259</sup>T Cells in Synovial Sarcoma Open
We evaluated the safety and activity of autologous T cells expressing NY-ESO-1c259, an affinity-enhanced T-cell receptor (TCR) recognizing an HLA-A2–restricted NY-ESO-1/LAGE1a–derived peptide, in patients with metastatic synovial sarcoma (…
View article: Figures S1-S7 from Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 <sup>c259</sup>T Cells in Synovial Sarcoma
Figures S1-S7 from Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 <sup>c259</sup>T Cells in Synovial Sarcoma Open
Figure S1. Consort diagram. Figure S2. Longitudinal analyses of persistence, memory cells and exhaustion marker expression. Figure S3. NY-ESO-1c259T cells exhibit and maintain polyfunctionality prior to and postinfusion. Figure S4. NY-ESO-…
View article: Figures S1-S7 from Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 <sup>c259</sup>T Cells in Synovial Sarcoma
Figures S1-S7 from Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 <sup>c259</sup>T Cells in Synovial Sarcoma Open
Figure S1. Consort diagram. Figure S2. Longitudinal analyses of persistence, memory cells and exhaustion marker expression. Figure S3. NY-ESO-1c259T cells exhibit and maintain polyfunctionality prior to and postinfusion. Figure S4. NY-ESO-…
View article: Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial
Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial Open
Affinity-optimized T cell receptors can enhance the potency of adoptive T cell therapy. Afamitresgene autoleucel (afami-cel) is a human leukocyte antigen-restricted autologous T cell therapy targeting melanoma-associated antigen A4 (MAGE-A…
View article: Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma
Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma Open
ClinicalTrials.gov, NCT01343043 , Registered 27 April 2011.
Initial safety assessment of MAGE-A4 SPEAR T-cells Open
Background: This ongoing study (NCT03132922) evaluates the safety and tolerability of genetically engineered autologous specific peptide enhanced affinity receptor (SPEAR) T-cells (MAGE-A4c1032T cells) directed towards a MAGE-A4 peptide ex…
View article: Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma Open
We evaluated the safety and activity of autologous T cells expressing NY-ESO-1c259, an affinity-enhanced T-cell receptor (TCR) recognizing an HLA-A2–restricted NY-ESO-1/LAGE1a–derived peptide, in patients with metastatic synovial sarcoma (…